Ceribell, Inc. AI Stock Analysis
Want to see CBLL full AI Analyst Report?
Ceribell, Inc. (CBLL) AI Stock Analysis
Ceribell, Inc.
(NASDAQ:CBLL)
The score is held back primarily by weak financial performance—especially sustained cash burn and deep losses—despite strong revenue growth and high gross margins. Technicals and a positive earnings call (raised guidance, margin outlook, lower expected interest expense, and cash-breakeven objective) provide support, while valuation remains constrained by lack of profitability and no dividend yield.
Ceribell, Inc. Key Performance Indicators (KPIs)
Revenue by TypeBreaks down sales into hardware, consumables (disposables), service contracts and any recurring software/subscription revenue. For Ceribell, distinguishing one‑time device sales from repeat purchases or subscription fees shows how predictable future cash flow is, where margins tend to be higher, and which parts of the business drive growth. Heavy reliance on one‑time device sales can make results lumpy, while growth in consumables and subscriptions signals stickier customers and better long‑term revenue visibility; reimbursement changes, hospital adoption rates, and supply‑chain constraints are key risks to monitor.
Ceribell’s growth is product‑led but subscriptions are scaling faster—both roughly doubled over two years—shifting the revenue mix toward more predictable, high‑margin recurring sales that support the raised 2026 guidance and sustained high‑80s gross margins. FDA clearances and NTAP reimbursement expand TAM and should accelerate adoption, but heavy operating spend, litigation costs, and very low current penetration mean revenue growth will likely precede GAAP profitability, with material upside from new product lines expected in 2027.
The FlyCeribell, Inc. (CBLL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 443.32K
- Price to Earnings (P/E)
- -14.3
- Beta (1Y)
- 0.79
- Revenue Growth
- 31.28%
- EPS Growth
- -34.52%
- Country
- US
- Employees
- 327
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Ceribell, Inc. Business Overview & Revenue Model
Company Description
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primar...
Ceribell, Inc. Earnings Call Summary
The call was strongly positive overall. CeriBell delivered approximately 30% revenue growth, record account additions, double-digit utilization growth, higher gross margins, raised full-year revenue guidance, and encouraging results from its delirium monitoring pilot. The company also outlined multiple product and market expansion initiatives for 2027. Offsetting factors included a wider net loss and adjusted EBITDA loss, operating expenses growing faster than revenue, ongoing litigation exposure, early-stage contributions from newer products, and the expectation that broad delirium adoption will take time.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
CeriBell expects full year 2026 revenue to range from $115 million to $117 million, up from prior guidance of $114 million to $117 million, representing annual growth of 29% to 31% over 2025; this range does not include material contributions from neonate, pediatric, or delirium products, which are expected to begin translating to revenue more meaningfully in 2027. Based on today's tariff policy and current inventory position, the company expects to maintain margins in the high 80% range going forward, expects interest expense to decrease materially going forward to less than $1 million annually, and remains committed to achieving cash flow breakeven with cash on hand. CeriBell expects many accounts to adopt its delirium monitoring solution quickly, but broad-scale conversion will occur over time, with a more granular perspective on anticipated revenue impact planned as part of 2027 financial guidance; VA commitments are expected to roll into the account base over the next 2 to 3 quarters or so, qEEG features will be released next year, and Omni will have a limited market release this quarter with the product expected to launch in 2027.
Ceribell, Inc. Financial Statement Overview
Summary
Rapid revenue growth and very strong gross margins are positives, and leverage appears modest. However, the company remains deeply unprofitable with widening losses, and cash flow is the key weakness with sustained and worsening operating and free cash flow burn in the TTM period.
Income Statement
46NeutralBalance Sheet
62PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 108.72M | 89.06M | 65.44M | 45.23M | 25.92M |
| Gross Profit | 97.04M | 78.27M | 56.75M | 38.16M | 21.49M |
| EBITDA | -71.26M | -50.18M | -37.32M | -26.51M | -35.06M |
| Net Income | -73.88M | -53.41M | -40.45M | -29.46M | -37.16M |
Balance Sheet | |||||
| Total Assets | 156.37M | 195.80M | 225.41M | 58.92M | 86.46M |
| Cash, Cash Equivalents and Short-Term Investments | 117.47M | 159.26M | 194.37M | 34.49M | 68.23M |
| Total Debt | 21.65M | 22.28M | 21.96M | 14.20M | 18.22M |
| Total Liabilities | 38.83M | 40.47M | 34.25M | 171.17M | 172.86M |
| Stockholders Equity | 117.54M | 155.34M | 191.16M | -112.25M | -86.40M |
Cash Flow | |||||
| Free Cash Flow | -58.70M | -41.58M | -36.38M | -30.14M | -32.52M |
| Operating Cash Flow | -56.01M | -40.81M | -35.04M | -29.16M | -32.00M |
| Investing Cash Flow | 68.77M | -118.14M | -1.60M | -1.76M | -1.40M |
| Financing Cash Flow | 5.50M | 5.05M | 196.52M | -2.82M | 49.80M |
Ceribell, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBLL, the sentiment is Positive. The current price of 27.80 is above the 20-day moving average (MA) of 27.10, above the 50-day MA of 25.46, and above the 200-day MA of 20.98, indicating a bullish trend. The MACD of 0.61 indicates Positive momentum. The RSI at 57.26 is Neutral, neither overbought nor oversold. The STOCH value of 82.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBLL.
Ceribell, Inc. Risk Analysis
Ceribell, Inc. disclosed 76 risk factors in its most recent earnings report. Ceribell, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCeribell, Inc. Peers Comparison
Overall Rating
GEHC79Outperform
PHG67Neutral- CBLL56Neutral
HYPR55Neutral
NPCE53Neutral
CLPT41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GEHC | 79Outperform | $37.82B | 17.43 | 19.85% | 0.18% | 6.87% | -2.26% |
| PHG | 67Neutral | $29.19B | 26.93 | 8.44% | 3.28% | ― | ― |
| CBLL | 56Neutral | $1.07B | -14.33 | -54.53% | ― | 31.28% | -34.52% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HYPR | 55Neutral | $72.24M | -2.35 | -82.89% | ― | 79.96% | 42.64% |
| NPCE | 53Neutral | $435.57M | -21.90 | -119.68% | ― | 11.59% | 31.90% |
| CLPT | 41Neutral | $281.12M | -7.58 | -170.24% | ― | 32.51% | -46.56% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CBLL | Ceribell, Inc. | 27.80 | 15.31 | 122.58% | |
| PHG | Koninklijke Philips N.V. | 30.20 | 2.20 | 7.86% | |
| CLPT | Clearpoint Neuro, Inc. | 9.17 | -6.33 | -40.84% | |
| HYPR | Hyperfine Inc. | 0.71 | -0.34 | -32.29% | |
| NPCE | Neuropace, Inc. | 12.52 | -0.29 | -2.26% | |
| GEHC | Ge Healthcare Technologies Inc. | 82.60 | 8.78 | 11.89% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026